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M mat ions in the luteinizing hormone (LI I) receptor gene have been found in patients with 
a h norm a lilies in I heir sexual differentiation. In this paper we review results obtained in the studies
ol these LI I receptor mutations. Activating and inactivating mutations are discussed with respect to 
the mechanism ol action of LI I/hunum chorionic gonadotrophin but also in light of their impact of the 
present knowledge ol the physiology of sex differentiation and gonadal function.
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Rotterdam, The Netherlands
In Ihe process of sex differentiation two major switches 
can be distinguished. First, expression of the SKY (sex- 
determining region Y) gene on the Y chromosome is 
responsible for induction of testis formation from the 
indifferent gonads (1, 2), a process that also requires 
other autosomal or X chromosomal genes. Subse­
quently, the differentiating testicular cells establish 
hormonal control of further development of Ihe 
urogenital trad and sinus. The Sertoli cells of the fetal 
testis secrete untLMiillcrian hormone (AMH), a member 
of the transforming growth lador-./ (TCil-Vi/aetivin 
family of growth anti differentiation factors t i l .  Anti- 
Miillerian hormone binds to an AMH receptor that is 
present in the mesenchymal cells surrounding the 
female anlagen of the urogenital trad, the Mullerian 
ducts (4. S). The action of AMH results in regression in 
(he Mullerian ducts in the male. Development of male 
internal and external genitalia is dependent on the 
Leydig cell protlncl testosterone, which in some large! 
tissues is converted to dihvdrotestosterone (b). The 
Wolffian duds, the anlagen of the male urogenital tract, 
develop into the epididymides, vasa deferentia and 
seminal vesicles. The other male internal and external 
genitalia are also formed under the iniluenee of 
androgens: the prostate, penis and scrotum.
The obligatory role of androgens in sex differentiation 
is exemplilied bv the female external phenotype of 
4h.\Y  individuals that are insensitive to androgens 
because of mutations in their androgens receptor gene
(7).
Androgens are produced bv a single cell type in the 
testis, the I.eydig cells (for reviews see Refs. S and
into the gonads during the period of formation of the 
bipotential gonads (10). Human fetal Leydig cells 
initially differentiate and proliferate under the influence 
of htYi (11), Subsequently, after the establishment of 
the pituitary-gonadal axis, LII comes into play. Fetal 
Leydig cell activity is responsible for virilization of the 
male internal and external genitalia. Postnatally and in 
childhood, LII levels are low. During puberty rising LH 
levels again stimulate Leydig cell to start producing 
androgens, which results in the establishment, of the 
adult male secondary sexual characteristics.
Both litXl and LH signal through the LH receptor. The 
LII receptor belongs to the class of GTP binding protein 
(Cl protein’l-coupled receptor that display specific fea­
tures such as a domain of seven transmembrane helices 
(12. 1 i). The LH rece 
for TSII and I\SH are characterized by an additional 
large extracellular domain that contains 14 leucine- 
rich repeats and is responsible for ligand binding (1 4 -  
17). The subgroup of Cl protein-coupled receptors 
transduces the signal of the hormone mainly to 
adenylyl cyclase through the stimulatory G protein 
t ;v In addition, TSH and LH have been shown to
* I
activate the phosphatidylinositide pathway, indicating 
involvement of ti,, (15, IS). Hither LH-or hCO  
stiinulated adenylyl cyclase results in an increase of 
the cellular cAMP level, activation of cAMP-dependent 
protein kinase and phosphorylation of several proteins. 
Recently, an interesting substrate for phosphorylation 
was detected in steroidogenic cell types. The protein, 
steroidogenic acute regulatory protein (StAR), is a 
mitochondrial protein with a short half-life (.19) that is 
involved in the transport of cholesterol through the 
inner mitochondrial membrane. Mutations in STAR
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that inactivate the protein also cause congenital lipoid 
adrenal hyperplasia (20), which indicates the impor­
tance of STAR in steroidogenesis. The STAR-activated 
transport of cholesterol results in increased availability 
of the lipid to the Leydig cell mitochondrial cytochrome 
P-450 cholesterol side-chain cleavage enzyme that 
converts cholesterol into pregnenolone. Pregnenolone 
subsequently diffuses out of the mitochondria to the 
smooth endoplasmic reticulum where it is converted to 
testosterone.
Luteinizing hormone receptor expression studies 
have been mainly performed in the rat and mouse. 
Leydig cell expression of LH receptor mRNA can be 
found as early as at 15 days post coitum in the rat (21). 
However, the alternatively spliced mRNA species 
expressed in these early Leydig cells do not encode the 
complete receptor protein molecule, and produce 
truncated LH receptors that are inactive because they 
cannot couple to Gs. Messenger RNA molecules that 
encode a functional full-length LH receptor are 
expressed approximately 1 day later (21); in the ovary 
this transition takes more than 2 weeks (22), The 
physiological significance of these alternative splicing 
products is unclear, although it has been suggested that 
the alternative splicing of gene products is a by-product 
of an alternative way of regulation of LH receptor gene 
expression (21, 22). Fetal testicular LH receptor mRNA 
expression has not been documented in humans. 
However, binding of hCG to fetal testicular tissue and 
the correlated hCG and testosterone levels during fetal 
life suggest that functional LH receptors are expressed in 
Leydig cells at an early fetal age of 9 weeks (1 1 ,2 3 , 24).
steroidogenesis in other organs such as the adrenal 
gland, in both syndromes, LH receptor function has 
been shown to be modified, in Ihe following sec!ions, 
mutational changes in the LI I receptor in these two 
syndromes and their consequnces for Leydig cell 
function will be dicussed.
Disorders of sex differentiation
Many disorders of male sex differentiation have been 
described, all of which are due to either insuflicient 
availability of testosterone (androgens) or the lack of 
response of the target tissues to this hormone. Muta­
tions in the androgen receptor gene lead to androgen 
insensitivity of target tissues, which causes partial or 
complete male pseudohermaphroditism (25). Before 
puberty a similar external phenotype is initially found 
in cases with dclicieney of the enzyme 5n-reduciase 
type 2 that converts testosterone to the more active 
metabolite dihydrotestosterone (f>), although at puberty 
the testes start to secrete high amounts of testosterone, 
which sometimes results in extensive virilization. Also, 
changes in the activity of steroidogenic enzymes in the 
testosterone synthesis pathway, such as Cl 7-204yase/ 
17a~hydroxylase or 3/^-hydroxysteroid dehydrogenase, 
affect male sex differentiation. Because these enzvme 
dysfunctions also manifest themselves in the adrenal 
gland, they also cause adrenal hyperplasia (26).
In two familial disorders— familial male-limited 
precocious puberty and Leydig cell hypoplasia—  
Leydig cell function is altered without changes in
Familial m ale-lim ited precocious puberty
Familial male-limited precocious puberty (I'MPP), also 
named lestotoxicosis, has been described initially in 
1981 (27), This familial form of precocious puberty is 
characterized by an excessive secretion of testosterone 
by Leydig cells in the absence of elevated levels of 
pituitary gonadotrophins (28, 29). ll is different from 
true (central) precocious puberty, which involves 
premature activation of the hypothalamic GnRH pulse 
generator ( SO). In FMPP. excessive androgen produc­
tion occurs probably also in the lelus. because enlarge­
ment of the external genitalia has been noted at birth in 
some cases (SI). A circulating testis-stimulating factor 
that activates only human. Leydig cells, but not rodent 
Leydig cells, has been suggested to be the cause of FMPP 
( 12), but this report was not confirmed. The increased 
testosterone production might also be the result of an 
inherent change in the Leydig cells themselves, and 
therefore the LH receptor gene of these patients was 
investigated,
Mutations in the LH receptor could change the 
behaviour of ihe receptor in such a manner that it 
would signal continuously through G., to the adenylyl 
cyclase system, activating the Leydig cells without the 
ligand being present. In their investigations of the o r  
adrenergic receptor, Lelkowitz and co-workers ( i i) had 
shown that changing an alanine residue in the third 
intracellular loop of this receptor to any other amino 
acid residue resulted in different levels of constitutive 
activation of the phosphatidylinositide pathway with­
out ligand being present. Furthermore in mice that 
dominantly express a coat-colour trait, an MSI I receptor 
gene that consititulively activates adenvlvl cvelase wasV * f '1 4 I*
described ( J4).
Familial diseases as a result of such conslitutivclv 
activated G protein'-coupled receptors had not been 
described at that time, but on the basis of these reports, 
DNA analysis of the LH receptor gene was undertaken 
with emphasis on the third intracellular loop and the 
sixth transmembrane segment. Two mutations were 
reported, methionine at position 571 to isoleucine ( Jr) 
and aspartate at position 578 to glycine t JS. Sb). When 
transfected into COS or HKK29 5 cell lines, the cells that 
expressed the mutant receptor species indeed showed an 
increased basal cAMP level when compared to cells 
expressing the wild-tvpe receptor (Fig. I ).
When hCG was added to the transfected cells, a dose- 
response relationship was found with an KDsn which is 
very similar to the KDSU of the wild-type receptor. To
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Fía. I. Mutation in patients wllh familial male-limited precocious 
puberty causes t’<iriNíítutivc UJ receptor activity. Hitman chorionic 
gonadotrophin thlV» I dependent eAMF production in cells expressing 
lilt* wild-type or m utant lmethionines ‘ 1 to Isoleudne or aspartate*' s to 
glycine) LH receptor. Mutant receptors show an Increased basal cAMl* 
production bul a decreased maximal response to h t \ l .  (Figure taken 
from Ret'. 54.)
date, eleven dillerenl LH receptor mutations in FMPP 
have been described (Fig. 2), Most imitations are found 
in the sixth transmembrane segment and Hanking 
third intracellular loop. However, two mutations
(methionine to threonine and isoleueine s-t to
leucine) were found in other transmembrane segments, 
the second and fifth, respectively* These findings 
indicate that the sixth transmembrane segment and 
the third intracellular loop are major determinants of (3
protein coupling in the LH receptor, but that the second 
and fifth transmembrane segments are also involved, 
Data obtained with other G protein-coupled receptors 
implicate similar receptor regions in G protein coupling 
(see Refs, 37 and 38). Careful examination of the amino 
acid changes found in FMPP patients reveals that 
although some alterations involve a major change of 
amino acid type, such as aspartate578 to glycine or 
tyrosine, or cysteine581 to arginine, other amino acid 
changes such as alanine568 to valine or isoleucine 5/5 to 
leucine, do not. it seems that any change of several 
amino acid residues may result in a constitutively active 
receptor. The receptor molecule appears to be finely 
tuned, and can be thought to be activated similar to a 
spring or mouse-trap when either the hormone binds or 
an amino acid is changed. The amino acid residues that 
are changed in FMPP patients are obvious candidates in 
future investigations of the structure-function relation- 
ship of the LH receptor during activation by LH or hCG.
it would appear that the LH receptor mutations found 
in FMPP patients are indeed the cause of their 
precocious puberty, but it is difficult to obtain formal 
proof. One of the experiments that could provide such 
proof would be a transgenic mouse with a targeted 
activating LH receptor gene mutation. In another 
approach, we have chosen to use a mouse Leydig cell 
line, MA-10 cells (39), to test the mutations that were 
found in FMPP patients. The MA-10 cells were 
transfected with wild-type and mutated LH receptor 
eDNA constructs, and basal and maximally hCG- 
stimulated pregnenolone production was determined. 
Because MA-10 cells carry the mouse wild-type LH 
receptor, the transfectcd cells partially mimic the 
situation in Leydig cells of an PMPP patient, where 
also both wild-type and mutated alleles are expressed. 
Figure 3 shows that mutated LH receptors have a
extracellular domain transmembrane domain
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receptor expression on basal cAMP and pregnenolone production by 
mouse tumour Leydig ceils (MA 1 0 ), Cells transfected with tvild-type 
and m utant LH receptors were incubated in the absence or presence oi 
a maximally stimulating dose of hCCï, Basal cAMP or pregnenolone 
production is expressed as a percentage of the maximal response to 
hCCi, Both cAMP and pregnenolone productions are increased in cells 
transfected with mutant receptor, in ihe absence o f h l ’il nr LII.
dominant phenotype; cells transfected with a constitu- 
lively active LH receptor show a higher cAMP level and, 
more importantly tor ihe FMPP phenotype, also a 
higher steroid production. These results demonstrate 
that in Leydig cells of FMPP patients the increased basal 
cAMP level in the absence of hormone will indeed result 
in increased testosterone production, and subsequently 
in precocious puberty.
Leydig cell hypoplasia
The clinical mirror-hnage of FMPP is ihe Leydig cell 
hypoplasia syndrome (LCH). Patients can present with a
external genita­
lia, or with a more severe form with complete male 
pseudohermaphroditism (40-47). The testes of the 
patients show low numbers of Leydig cells in the 
mildly affected patients, to a complete absence of adult 
Leydig cells in the pseudo-hermaphrodites. The syn­
drome of Leydig cell hypoplasia is an autosomal 
recessive condition. In some studies testicular LH 
binding was absent, which could either be the cause 
or the consequence of the absence of Leydig cells (47). 
In analogy with the studies on FMPP. the LII receptor 
gene in LCH patients was investigated (4N. 49). In 
contrast with the LH receptor gene in FMPP patients, it 
can be expected that DNA changes (he result in a loss of 
function of the LH receptor gene will be found anywhere 
in the gene and may range from amino acid changes, to 
shifted reading frames or deletions of part of the gene. 
Two groups have reported on LH receptor gene 
mutations in LCH patients. In one of these papers, two 
4b,XY sisters born from consanguineous parents were 
found to be homozygous for a missense mutation that
resulted in the change of alanine at position 59 5, 
located just outside the sixth transmembrane segment, 
into a proline residue (Figure 4 )(48). When expressed 
in transfected cells, this mutated LH receptor was found 
to bind hCG with a normal Kj. although the receptor 
was expressed at a much lower level than the wild-type 
receptor. However, the proline residue changed (he LII 
receptor in such a way that, in spite id* the higlwiffmity 
hCCi binding, no eouping to adenylyl cyclase could be 
demonstrated in the absence or presence of hCG (Fig. 4). 
In another patient the situation was more complex (49). 
One allele of the LH receptor gene was found to contain 
a nonsense mutation resulting in the introduction of a 
stop codon at position 545 in the lifth transmembrane 
segment of the transmembrane domain. Similar to the
w |  I  I
alanine’* to proline mutation, in vitro expression of 
this truncated receptor showed diminished binding with 
the same affinity compared to the wild-type Li { receptor, 
and no coupling to adenylyl cyclase. The other LH 
receptor allele did not show the same mutation, 
suggesting that the patients were compound hetero­
zygotes. The identity of the mutation in this LI! receptor 
allele has not been established yet 149), Two additional 
mutations (asparagine'**11 to serine and serine Mi> to 
tyrosine) have been published recently in an abstract 
(50). The mutation at position 291 lies in the 
extracellular domain, and this receptor molecule may 
be expected to have lost ligand binding. 'This mutation 
has not been tested in vitro, however. The seriuehlh to 
tyrosine mutation showed similar behaviour in vitro to 
the LH receptors carrying an alanine^ to proline 
mutation or a stop codon at position 545.
The mutations described above were found in severe 
cases of LCH. In patients that are affected more mildly, 
amino acid changes may be found that do not abolish 
receptor function completely, but rather may result in 
decreased activity such as diminished LH binding 
affinity or less-efficient t! protein coupling. Milder 
mutations may allow correlations beiween the proper­
ties of the amino acid residues that have changed and 
the severity of the LCH syndrome, and hopefully will
f  4
give directions toward the further functional character­
ization of the receptor subdomains, such as the domains
involved in the regulation of receptor transport from ihe 
endoplasmic reticulum to the plasma membrane or 
glycosylation of the extracellular ligand binding 
domain.
Concluding remarks
Although identification of LH receptor gene mutations 
has just started, a distinct pattern of mutations appears 
to evolve. Fourteen mutations that have been published 
are located in the transmembrane domain of the LH 
receptor; only one mutation (asparagine*111 to serine) 
changes the extracellular LH binding domain, although 
the effect of this mutation on LH receptor function was
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not tested in vitro. However. this overrepresentation of 
(lit* transmembrane domain should not in* emphasized 
loo much because this region was tlu* domain that was 
lirsl subjected to UN A analysis, Rm*ntly, the intron- 
exon structure of tin* oilier exons of the large human hi I 
reeeplor gent* has been determined, allowing the study 
of the other exons of the LI 1 receptor gene (SI). Most LI 1 
receptor mutations found in FMPP patients are located 
in the third intracellular loop or in the sixth transmem- 
brane segment i!;ig> 2). This linding underscores the 
Importance of this receptor region in Cl protein coupling, 
as was already suggested from studies using site- 
directed mutagenesis (see Kef. 52), However, it is of 
interest that the two imitations that were identified in 
the l.CTl patients both lie in the last exon that encodes 
the transmemhrane domain. It remains to be estab­
lished by the identification of other Lt'H LI I receptor 
gene mutations whether a selective pressure exists 
against mutations in the other exons that encode the
extracellular Llf/ht'C* binding domain.
Now that the molecular basis of the syndromes of 
FMPP and Lt’H has been established, conclusions can be 
drawn about the relative importance of LH/ht'C! during 
sexual differentiation of the male and the role of
androgens in spermatogenesis, In the LOT patients 
with the alanine^* lo proline mutation the absence of 
LH/hCti stimulation of Leydig cells did not lead to a 
complete absence of androgens. The presence of the 
androgen-dependent epididymides and vasa deferentia
assocn
that there is autonomous (LH/hC(l-independent) andro­
gen production by Leydig cells during fetal male sex 
differentiation. Probably this autonomous androgen 
production is relatively low, and only effective at a small 
distance from the developing testis, as indicated by the 
absence of oilier androgen-dependent organs such as 
the prostate or seminal vesicles. Epididymides and vasa 
deferentia are not found in patients that suffer from 
complete androgen insensitivity and do not have a 
functional androgen receptor gene (25). Recently, 
differentiation of epididymides and vasa deferentia was
in a mouse line without a functional1 L 1/ '
glycoprotein rv-subunit gene (53). Because mice do 
not have a hCt] homologue, this androgen-induced
causes me very cany precocious puoeriy cioes not seem 
to have adverse effects in adult life. Patients with PMPP
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have I ho short stature associated with precocious 
puberty but abnormalities such as Leydig cell neoplasia 
or infertility have not been reported, with the exception 
of one individual in a large pedigree who was reported 
to be infertile (28). Postpubertal LH-stinuilated andro­
gen levels are much higher than the androgen 
productions in the FMPP boys, and may explain the 
absence of effects of the activating L11 receptor 
mutations in adult life,
The female carriers of an FMPP LI I receptor gene 
mutation, which in men leads to precocious puberty, 
seem to be without symptoms. In the light of the precise 
regulation of the menstrual cycle in women, this seems 
puzzling. Although no studies of female carriers of 
FMMP I i i  receptor mutations have been reported, 
expression of constitutively active LM receptors in 
preovulatory follicles might lead to premature ovula­
tions. However, there is no indication of impaired 
fertility in the female carriers. Possibly, at the time of 
ovulation the follicular LI1 receptors have to be 
stimulated to a high degree to induce ovulation. As 
can be seen readily from the hC(5 dose-response curves 
depicted in Fig. I , the basal cAMP level is increased in 
cells expressing a constitutively active receptor, but an
paper are parlially supported by The Netherlands Organization fur 
Scientific Research through NWO-MW,
y  i  *increase
enhancement of cAMP production, thus allowing 
granulosa cells of female FMPP carriers to respond 
normally to the ovulatory LH peak.
> 1.1 T roronlnr muhilinns has UO effect 00
• is not
expressed in ovaries before birth (2 1 ). However, a 4b, 
XX sister in the family described by Kremer el al. (48} 
was found to be homozygous for the same inactivating 
LH receptor gene mutation, and presents with primary 
amenorrhoea, but has normally developed sex char­
acteristics (Dr S Toledo, pers. comm.) (48), This is 
consistent with the requirement for an active LH signal 
transduction system for ovulation to occur, In this 
respect it is of interest to note that recently an 
inactivating mutation in the FSII receptor gene has 
been found in women with ovarian dysgenesis. In these 
women, the inability of the ovaries to respond to FKH 
results in the absence of follicle growth, low gonadal 
hormone production and variably developed secondary 
sex characteristics in the presence of high levels of FSH 
and LIL It is tempting to speculate that other patients 
with female infertility may also be carriers of more or 
less severe LH or FSH receptor gene mutations, A 
combination of two mutations with a mild phenotype 
(two alleles) or of one mutation with a severe phenotype 
(one allele) could lead to a decreased LH or FSH receptor 
response and disturbance of the precise timing that is 
necessary for ovulation of the preovulatory follicle.
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